"Arrowhead seeks approval to begin RNAi therapy trial for obesity treatment" was originally created and published by Clinical ...

Not exactly known for its dealmaking, Sarepta Therapeutics has thrown down a massive wad of cash to work with Arrowhead ...

Efficient RNA interference in Caenorhabditis elegans requires a distinct class of secondary short interfering RNA. Although many proteins involved in RNAi were initially studied in the context of ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: ...

Gómez, Isaura Torres Ruiz, Orville Hernandez Muñoz, Jose F. Garcia, Ana María Restrepo, Angela and McEwen, Juan G. 2013. RNAi technology targeting Pb<i>GP</i>43 and ...

It has only been 5 years since Tom Tuschl and colleagues showed that the RNA interference (RNAi) pathway was functional in cultured mammalian cells, and that it was possible to trigger this ...

View full profile. Learn about our editorial policies. The natural RNAi mechanism can be directed by either short interfering RNA (siRNA) or microRNA (miRNA). 1 There are four key steps in the RNAi ...